Detailed entry information

Protein Information (annotations from UniProt)

Database IDHIV0001478
UniProt IDP23458
Primary gene name(s)JAK1
Synonym gene name(s)JAK1A, JAK1B
Protein nameTyrosine-protein kinase JAK1
Protein functionTyrosine kinase of the non-receptor type, involved in the IFN-alpha/beta/gamma signal pathway, PubMed:7615558. Kinase partner for the interleukin, IL-2 receptor, PubMed:11909529. {ECO:0000269|PubMed:11909529, ECO:0000269|PubMed:7615558}.
Subcellular locationEndomembrane system;
Peripheral membrane protein. Note=Wholly intracellular, possibly membrane associated.
ECO codeClick here for more information.
Amino acid sequence
FASTA format: P23458
Gene Ontology
(Biological Process)
Complete annatation
cell differentiation [GO:0030154];
cell migration [GO:0016477];
innate immune response [GO:0045087];
interferon-gamma-mediated signaling pathway [GO:0060333];
interleukin-2-mediated signaling pathway [GO:0038110];
intracellular signal transduction [GO:0035556];
MAPK cascade [GO:0000165];
peptidyl-tyrosine autophosphorylation [GO:0038083];
positive regulation of sprouting angiogenesis [GO:1903672];
protein phosphorylation [GO:0006468];
regulation of cell proliferation [GO:0042127];
regulation of interferon-gamma-mediated signaling pathway [GO:0060334];
regulation of type I interferon-mediated signaling pathway [GO:0060338];
response to antibiotic [GO:0046677];
transmembrane receptor protein tyrosine kinase signaling pathway [GO:0007169];
type I interferon signaling pathway [GO:0060337]
Gene Ontology
(Molecular Function)
Complete annatation
ATP binding [GO:0005524];
growth hormone receptor binding [GO:0005131];
metal ion binding [GO:0046872];
non-membrane spanning protein tyrosine kinase activity [GO:0004715];
protein phosphatase binding [GO:0019903];
protein tyrosine kinase activity [GO:0004713];
Ras guanyl-nucleotide exchange factor activity [GO:0005088];
receptor binding [GO:0005102];
ubiquitin protein ligase binding [GO:0031625]
Gene Ontology
(Cellular Component)
Complete annatation
cytoplasm [GO:0005737];
cytoskeleton [GO:0005856];
cytosol [GO:0005829];
endomembrane system [GO:0012505];
extrinsic component of cytoplasmic side of plasma membrane [GO:0031234];
focal adhesion [GO:0005925];
nucleus [GO:0005634]
Protein-protein interaction109919
Phylogenetic treeP23458
HIV replication factor status Zhou et al., Cell. Host. Microbe., 2008
      Yes - Two siRNA pools inhibit HIV replication and inhibition of Tat-mediated transactivation of the HIV LTR is also observed
Brass et al., Science, 2008
Smith et al., J. Immunol, 2010
gene status
Lu et al., J. Virol., 2011
      Folds changes 8h: unknown; Folds changes 16h: unknown; Tested: unknown;
Schoggins JW and Rice CM, Curr. Opin. Virol., 2011
      Targeted viruses: unknown
      Viral life cycle: unknown
      Mechanism related to antiviral activity: unknown
Anti-viral restriction factor Liu et al., Retrovirology, 2011
      unknown (Triplicates)

Gene Expression Profile       top

            Up-regulated;            Down-regulated

For brief introduction to each study, please go to the help page.

Gene expression during HIV latency

(1). Mohammadi et al., PLoS Pathog., 2014

Differentially expressed transcripts (Pairwise) during latency and subsequent viral reactivation using several agents - Primary CD4+ T-cell based model

DMSO: Dimethyl suloxyde (negative control) - 0.0033% final
SAHA: Vorinostat (Histone deacetylase inhibitor) - 0.5 μM
CD3: TCR Stimulation by IL-2+ antiCD3/anti-CD28 antibodies
IL7: Interleukin-7 based stimulation
DISU: Disulfiram (alcohol dehydrogenase inhibitor) - 0.5 μM
AZA: 5-azacytidine (AZA; DNA methylation inhibitor) - 1 μM
Experimental Condition Log2 Fold Change P value Adjusted P value
AZA vs. CD3-0.1444319395054030.6588027083876030.753015968067061
AZA vs. DISU0.1814887444816590.4725169524448160.927210205381308
AZA vs. IL7-0.2275092403123640.2353945452521980.990920320206469
AZA vs. SAHA-0.1359252170121410.5763686688886310.859561599164171
DISU vs. CD30.3128299169531470.3896939156454570.523924909422013
DISU vs. IL7-0.418080860547810.09670459901879020.411349274889465
DISU vs. SAHA-0.3159771099995640.2778539361383180.65800387673485
DMSO vs. AZA0.02602662176805530.8759419847429451
DMSO vs. CD30.1574385789671540.6223075874578030.715599099691001
DMSO vs. DISU-0.1577072578812760.5172949107591280.914196078390533
DMSO vs. IL7-0.2461345690871510.1697368149560070.679984715775129
DMSO vs. SAHA-0.1681830790365260.4744345878580580.799397025482796
HIV vs. Mock in Activation0.3412378688059170.5838037215788890.999983755607037
HIV vs. Mock in Latency0.06801180209967050.6791697129626230.999834320637052
IL7 vs. CD3-0.07579631476542460.8137161452802080.878969718919921
SAHA vs. CD3-0.01626346503118110.9632541921361410.975422703634703
SAHA vs. IL70.08782723953585860.7177253715395190.870275032183115
(2). Iglesias-Ussel et al., J. Virol., 2013

Up and Downregulated transcripts during Latency (Latently infected CD4+ T cells vs Uninfected)- Primary CD4+Tcell based model
Log2 Fold Change P Value
unknown unknown

Gene expression during HIV infection and replication

(1). Imbeault et al., PloS Pathog., 2012

Transcriptomic profiling of HIV-1 infected CD4+ T cells - Primary CD4+ T cells
Experiment type Log2 Fold Change P Value Adjusted P Value
Infected vs. Mock unknown unknown unknown
Infected vs. Bystander unknown unknown unknown
(2). Lefebvre et al., J. Virol., 2011

Transcriptome analysis of T-cell line (Sup T1)
Log2 Fold Change unknown
(3). Li et al., J. Immunol., 2013

Lymphatic tissue
Acute Fold Change Acute P Value Asymt Fold Change Asypt P Value AIDS Fold Change AIDS P Value
unknown unknown unknown unknown unknown unknown
(4). Chang et al., MBio., 2011

Transcriptome analysis of T-cell line (Sup T1)

Derived from Sherrill-Mix et al., BMC Retrovirol., 2015 cross validation
Up-regulated (True) TRUE
(5). Sherrill-Mix et al., BMC Retrovirol., 2015

Deep RNA-seq analysis of primary human T cell infected with low passage HIV isolate HIV89.6 - Primary CD4+ T cell based
Test Status Log2 Fold Change P Value
OK -0.397675 0.00132191
(6). Rotger et al., PLoS Pathog., 2010

Genome-wide mRNA expression of CD4+ T cells from HIV-infected patient
(Genes differentially expressed (at adjusted p<0.01) according to the empirical Bayes approach)
Log2 Fold Change P Value
unknown unknown

Proteomic/Transcriptomics studies indicating differentially expressed genes mediated by HIV

(1). Greenwood et al., Elife, 2016

Activated (CD3/CD28) Primary human CD4+ T cells infected with pNL4-3-dE-EGFP. The table shows the complete (unfiltered) TMT (tandem mass tag)-based proteomic time course dataset
6 h 24 h 48 h 72 h RTi
0.956 1.18 0.92 1.049 1.078
(2). Navare et al., Virology, 2012

SUP-T1 cell line
FC-4hpi P-value FC-8hpi P-value FC-20hpi P-value Category
unknown unknown unknown unknown unknown unknown unknown
(3). Hyrcza et al., J. Virolo., 2007

Primary human CD4+ and CD8+ T Cells
Affymetrix Prob ID Fold Change In CD8? Category
unknown unknown unknown unknown

Protein Overview       top

Drug-protein Interaction       (annotations from DrugBank)      top

Drugbank ID Drug Name Drug Status Pharmacological Action Drug Action
DB04716 2-(1,1-DIMETHYLETHYL)9-FLUORO-3,6-DIHYDRO-7H-BENZ[H]-IMIDAZ[4,5-F]ISOQUINOLIN-7-ONE experimental unknown unknown
DB08183 3-{(3R,4R)-4-methyl-3-[methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]piperidin-1-yl}-3-oxopropanenitrile experimental unknown unknown
DB08877 Ruxolitinib approved yes inhibitor
DB08895 Tofacitinib approved, investigational yes inhibitor

Protein Secondary Structure       (annotations from PDB)      top

PDB Accession Method Resolution Chain Structure Preview
3EYG X-ray 1.9Å A=865-1154.
3EYH X-ray 2.0Å A=865-1154.
4E4L X-ray 2.0Å A/B/D/E=854-1154.
4E4N X-ray 1.9Å A/B=854-1154.
4E5W X-ray 1.8Å A/B=854-1154.
4EHZ X-ray 2.1Å A/B/C/D=854-1154.
4EI4 X-ray 2.2Å A/B=854-1154.
4FK6 X-ray 2.2Å A/B=854-1154.
4GS0 X-ray 1.8Å C=1033-1036.
4I5C X-ray 2.1Å A/B=854-1154.
4IVB X-ray 1.9Å A/B=854-1154.
4IVC X-ray 2.3Å A/B=854-1154.
4IVD X-ray 1.9Å A/B=854-1154.
4K6Z X-ray 2.7Å A=854-1154.
4K77 X-ray 2.4Å A/B=854-1154.
4L00 X-ray 1.8Å A/B=561-860.
4L01 X-ray 1.9Å A/B=561-860.
5E1E X-ray 2.3Å A/B=865-1154.
5HX8 X-ray 2.2Å A/B=854-1154.
5IXD X-ray 2.8Å A=35-559.
5IXI X-ray 2.5Å A=35-559.
5L04 X-ray 2.1Å A=31-577.

HIV-1 Interaction       (annotations from NCBI HIV-1 Interaction Database)      top

HIV Partner Interaction Type PubMed
Tat modulates 18187620
Tat regulated by 18976975
Envelope surface glycoprotein gp120 upregulates 12089333
HIV-1 virus replication enhanced by expression of human gene 18187620
HIV-1 virus replication inhibited by expression of human gene 17560945
matrix activates 22558273

Metabolic/Signalling Pathway       (annotations from KEGG database)      top

Pathway Accession Number Description
hsa01521 EGFR tyrosine kinase inhibitor resistance - Homo sapiens (human)
hsa04151 PI3K-Akt signaling pathway - Homo sapiens (human)
hsa04380 Osteoclast differentiation - Homo sapiens (human)
hsa04550 Signaling pathways regulating pluripotency of stem cells - Homo sapiens (human)
hsa04621 NOD-like receptor signaling pathway - Homo sapiens (human)
hsa04630 Jak-STAT signaling pathway - Homo sapiens (human)
hsa04658 Th1 and Th2 cell differentiation - Homo sapiens (human)
hsa04659 Th17 cell differentiation - Homo sapiens (human)
hsa05140 Leishmaniasis - Homo sapiens (human)
hsa05145 Toxoplasmosis - Homo sapiens (human)
hsa05152 Tuberculosis - Homo sapiens (human)
hsa05160 Hepatitis C - Homo sapiens (human)
hsa05161 Hepatitis B - Homo sapiens (human)
hsa05162 Measles - Homo sapiens (human)
hsa05164 Influenza A - Homo sapiens (human)
hsa05166 HTLV-I infection - Homo sapiens (human)
hsa05168 Herpes simplex infection - Homo sapiens (human)
hsa05169 Epstein-Barr virus infection - Homo sapiens (human)
hsa05200 Pathways in cancer - Homo sapiens (human)
hsa05203 Viral carcinogenesis - Homo sapiens (human)
hsa05212 Pancreatic cancer - Homo sapiens (human)